On March 5, 2019 Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported that Jeff Albers, Blueprint Medicines’ Chief Executive Officer, will present a company overview at the 39th Annual Cowen & Co.Health Care Conference on Tuesday, March 12, 2019 at 8:40 a.m. ET (Press release, Blueprint Medicines, MAR 5, 2019, Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference [SID1234533970]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 30 days following the presentation.

On March 5, 2019 Alexion Pharmaceuticals (Nasdaq: ALXN) reported that management will present at the Cowen 39th Annual Health Care Conference in Boston, MA on Tuesday, March 12, 2019 at 11:20 a.m., ET (Press release, Alexion, MAR 5, 2019, https://news.alexionpharma.com/press-release/financial-news/alexion-present-cowen-39th-annual-health-care-conference [SID1234533987]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An audio webcast of the presentation will be available live. You can access the webcast at: View Source An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

On March 5, 2019 Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, reported that management will present a company overview at the following investor conferences (Press release, Aura Biosciences, MAR 5, 2019, View Source [SID1234534010]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 10:00 a.m. Eastern Time in Boston, MA

Oppenheimer’s 29th Annual Healthcare Conference on Tuesday, March 19, 2019, at 9:10 a.m. Eastern Time in New York, NY

On March 5, 2019 Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, reported that the Company will host a conference call and live webcast on Tuesday, March 12, 2019 at 5:00 p.m (Press release, Bellicum Pharmaceuticals, MAR 5, 2019, View Source [SID1234533955]). Eastern to report its fourth quarter and full year 2018 financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, participants should dial 877-407-3103 (U.S. domestic) and 201-493-6791 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investors & Media section of the Bellicum website for at least two weeks following the call.

On March 5, 2019 Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported that Gavin Bennett, Ph.D., Bicycle’s Director of Preclinical Development and Project leader for BT5528, will present at the 9th Annual World ADC Conference in London (Press release, Bicycle Therapeutics, MAR 5, 2019, View Source [SID1234533971]). The presentation, focused on Bicycle’s pre-clinical BT5528 program for the treatment of solid tumours, will take place at 11:30 a.m. GMT on Wednesday, March 6.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We expect BT5528 to be Bicycle’s second clinical oncology product candidate and will build on the ongoing Phase I/IIa clinical study with BT1718. We are very excited about its potential to treat solid tumours," said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. "Preclinical data from our BT5528 program shows target-dependent anti-tumour activity across a range of EphA2-expressing tumour models without evidence of the profound toxicity seen with previous clinical-stage antibody drug conjugates targeting EphA2."

Dr. Bennett has also been invited to chair the "Discovery" track sessions at the conference.